Grail vs MDxHealth
Grail reported revenue of $147 million in fiscal 2025, 1.4 times MDxHealth's $108 million in fiscal 2025. Grail's revenue grew 17.2% in its latest year, and MDxHealth's grew 19.8%. Grail had an operating margin of -382.0%, against -13.4% at MDxHealth. Free cash flow was −$300 million at Grail and −$3 million at MDxHealth.
Side by side
| Grail | MDxHealth | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $147M | $108M |
| Revenue growth | 17.2% | 19.8% |
| Revenue growth a year, last 5 years | — | 42.3% |
| Gross margin | — | 64.5% |
| Operating margin | −382.0% | −13.4% |
| Net margin | −277.5% | −31.1% |
| Free cash flow | −$300M | −$3M |
| Free cash flow margin | −203.8% | −3.1% |
| Return on capital | — | −41.8% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 15.2% | 52.0% |
| Last close | $104.84 | $0.12 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $31.0 million | bought $991,189, sold $0 |
| Piotroski F-score | — | 3 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
GrailMDxHealth
Operating margin
Percent of revenue
GrailMDxHealth
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
GrailMDxHealth